From Medscape Gastroenterology

Coverage from

Advances in Inflammatory Bowel Diseases (AIBD) 2019

December 12 - 14, 2019; Orlando, Florida

December 12 - 14, 2019 Orlando, Florida
  • AIBD 2019 Biosimilar for Crohn's Noninferior to Adalimumab A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.

Conference News

Popular Inflammatory Bowel Disease News

Medscape Gastroenterology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Related Coverage